564 related articles for article (PubMed ID: 33022971)
1. The Immune Microenvironment in Pancreatic Cancer.
Huber M; Brehm CU; Gress TM; Buchholz M; Alashkar Alhamwe B; von Strandmann EP; Slater EP; Bartsch JW; Bauer C; Lauth M
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33022971
[TBL] [Abstract][Full Text] [Related]
2. Strategies for Increasing Pancreatic Tumor Immunogenicity.
Johnson BA; Yarchoan M; Lee V; Laheru DA; Jaffee EM
Clin Cancer Res; 2017 Apr; 23(7):1656-1669. PubMed ID: 28373364
[TBL] [Abstract][Full Text] [Related]
3. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
[TBL] [Abstract][Full Text] [Related]
4. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
5. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells.
Mota Reyes C; Teller S; Muckenhuber A; Konukiewitz B; Safak O; Weichert W; Friess H; Ceyhan GO; Demir IE
Clin Cancer Res; 2020 Jan; 26(1):220-231. PubMed ID: 31585935
[TBL] [Abstract][Full Text] [Related]
7. Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer.
Ahmad RS; Eubank TD; Lukomski S; Boone BA
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34204306
[TBL] [Abstract][Full Text] [Related]
8. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi M; Bartholin L; Neuzillet C
World J Gastroenterol; 2018 May; 24(20):2137-2151. PubMed ID: 29853732
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer.
Li C; Cui L; Yang L; Wang B; Zhuo Y; Zhang L; Wang X; Zhang Q; Zhang S
Pancreas; 2020 Jan; 49(1):120-127. PubMed ID: 31856087
[TBL] [Abstract][Full Text] [Related]
10. Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion.
Yang Y; Stang A; Schweickert PG; Lanman NA; Paul EN; Monia BP; Revenko AS; Palumbo JS; Mullins ES; Elzey BD; Janssen EM; Konieczny SF; Flick MJ
Cancer Res; 2019 Jul; 79(13):3417-3430. PubMed ID: 31048498
[TBL] [Abstract][Full Text] [Related]
11. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
12. Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma.
Pandey V; Storz P
Expert Rev Anticancer Ther; 2019 Jun; 19(6):473-482. PubMed ID: 31148495
[No Abstract] [Full Text] [Related]
13. Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification.
Chen Y; Chen D; Wang Q; Xu Y; Huang X; Haglund F; Su H
Front Immunol; 2021; 12():719105. PubMed ID: 35111149
[TBL] [Abstract][Full Text] [Related]
14. Gamma-delta T cells stimulate IL-6 production by pancreatic stellate cells in pancreatic ductal adenocarcinoma.
Seifert AM; List J; Heiduk M; Decker R; von Renesse J; Meinecke AC; Aust DE; Welsch T; Weitz J; Seifert L
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3233-3240. PubMed ID: 32865617
[TBL] [Abstract][Full Text] [Related]
15. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.
Lafaro KJ; Melstrom LG
Am J Pathol; 2019 Jan; 189(1):44-57. PubMed ID: 30558722
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.
Foucher ED; Ghigo C; Chouaib S; Galon J; Iovanna J; Olive D
Front Immunol; 2018; 9():1044. PubMed ID: 29868007
[TBL] [Abstract][Full Text] [Related]
17. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.
Zhang L; Wang W; Wang R; Zhang N; Shang H; Bi Y; Chen D; Zhang C; Li L; Yin J; Zhang H; Cao Y
Mol Ther; 2021 Feb; 29(2):744-761. PubMed ID: 33130310
[TBL] [Abstract][Full Text] [Related]
18. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
19. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Zhu Y; Knolhoff BL; Meyer MA; Nywening TM; West BL; Luo J; Wang-Gillam A; Goedegebuure SP; Linehan DC; DeNardo DG
Cancer Res; 2014 Sep; 74(18):5057-69. PubMed ID: 25082815
[TBL] [Abstract][Full Text] [Related]
20. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer.
De Sanctis F; Lamolinara A; Boschi F; Musiu C; Caligola S; Trovato R; Fiore A; Frusteri C; Anselmi C; Poffe O; Cestari T; Canè S; Sartoris S; Giugno R; Del Rosario G; Zappacosta B; Del Pizzo F; Fassan M; Dugnani E; Piemonti L; Bottani E; Decimo I; Paiella S; Salvia R; Lawlor RT; Corbo V; Park Y; Tuveson DA; Bassi C; Scarpa A; Iezzi M; Ugel S; Bronte V
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
